Issue 128 • March 2023

Inside the hunt for an Alzheimer’s disease vaccine

4D Molecular’s Fabry gene therapy program on FDA clinical hold

Price is key for market adoption of Amgen’s Amjevita

In association with

‘Right shoring’ API production in Europe

Amidst rising inflation and ongoing drug shortages, is the EU at risk of getting ‘right-shoring’ wrong?

In association with

02/23/2024 23:27:36
  • Home | ‘Right shoring’ API production in Europe
  • In this issue
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • Industry news
  • The pharma industry briefing
  • HOF Sonderanlagenbau
  • BEA Technologies
  • Comment
  • 4D Molecular’s Fabry gene therapy program on FDA clinical hold
  • Price is key for wider market adoption of Amgen’s Amjevita
  • Wegovy: the latest weight loss fad
  • PROTAC development gains momentum, but clinical performance is poor
  • FDA head Califf on tighter accelerated approvals and lower drug prices
  • In Depth
  • ‘Right shoring’ API production in Europe
  • Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?
  • DCTs in 2023: New year’s resolutions for decentralised clinical trials
  • Inside the hunt for an Alzheimer’s disease vaccine
  • Are we entering the era of biologics for COPD?
  • CMO Moves: Regulatory catalysts for drug manufacturing – February
  • Events
  • Next issue
02/24/2023 00:00:00